Purification of interferon alfa-2b using ionic liquid-based technologies

Detalhes bibliográficos
Autor(a) principal: Castro, Leonor S.
Data de Publicação: 2021
Outros Autores: Sousa, Guilherme L., Pereira, Patrícia, Neves, Márcia C., Freire, Mara G., Pedro, Augusto Q.
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10773/32877
Resumo: The development of protein-based biopharmaceuticals and their introduction on modern medicine brought enormous benefits to the treatment of life-threatening diseases such as cancer, diabetes and neurodegenerative disorders. However, their current high-cost still limits their widespread use. While significant advances at the upstream level have occurred, current purification strategies are unable to cope with high product concentrations resorting to cost-effective approaches. This work entails the development of sustainable downstream processing methodologies for recombinant interferon (IFN) α-2b derived from Escherichia coli using ionic liquids, either by exploring their application as adjuvants in polymer-polymer aqueous two-phase systems (ATPS) or as chromatographic ligands covalently attached in silica (supported ionic liquids - SILs). Overall, our results demonstrate the high potential exhibited by ionic liquids toward the preparative purification of the recombinant IFN α-2b biopharmaceutical.
id RCAP_fcc1629a18596276f693ff254aee19a0
oai_identifier_str oai:ria.ua.pt:10773/32877
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Purification of interferon alfa-2b using ionic liquid-based technologiesBiopharmaceuticalsPurificationSupported ionic liquidsChromatographyAqueous twophase systemsIFNα-2bThe development of protein-based biopharmaceuticals and their introduction on modern medicine brought enormous benefits to the treatment of life-threatening diseases such as cancer, diabetes and neurodegenerative disorders. However, their current high-cost still limits their widespread use. While significant advances at the upstream level have occurred, current purification strategies are unable to cope with high product concentrations resorting to cost-effective approaches. This work entails the development of sustainable downstream processing methodologies for recombinant interferon (IFN) α-2b derived from Escherichia coli using ionic liquids, either by exploring their application as adjuvants in polymer-polymer aqueous two-phase systems (ATPS) or as chromatographic ligands covalently attached in silica (supported ionic liquids - SILs). Overall, our results demonstrate the high potential exhibited by ionic liquids toward the preparative purification of the recombinant IFN α-2b biopharmaceutical.FEUP2022-01-12T14:24:49Z2021-06-01T00:00:00Z2021-06conference objectinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10773/32877engCastro, Leonor S.Sousa, Guilherme L.Pereira, PatríciaNeves, Márcia C.Freire, Mara G.Pedro, Augusto Q.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-06T04:34:48Zoai:ria.ua.pt:10773/32877Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-06T04:34:48Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Purification of interferon alfa-2b using ionic liquid-based technologies
title Purification of interferon alfa-2b using ionic liquid-based technologies
spellingShingle Purification of interferon alfa-2b using ionic liquid-based technologies
Castro, Leonor S.
Biopharmaceuticals
Purification
Supported ionic liquids
Chromatography
Aqueous twophase systems
IFNα-2b
title_short Purification of interferon alfa-2b using ionic liquid-based technologies
title_full Purification of interferon alfa-2b using ionic liquid-based technologies
title_fullStr Purification of interferon alfa-2b using ionic liquid-based technologies
title_full_unstemmed Purification of interferon alfa-2b using ionic liquid-based technologies
title_sort Purification of interferon alfa-2b using ionic liquid-based technologies
author Castro, Leonor S.
author_facet Castro, Leonor S.
Sousa, Guilherme L.
Pereira, Patrícia
Neves, Márcia C.
Freire, Mara G.
Pedro, Augusto Q.
author_role author
author2 Sousa, Guilherme L.
Pereira, Patrícia
Neves, Márcia C.
Freire, Mara G.
Pedro, Augusto Q.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Castro, Leonor S.
Sousa, Guilherme L.
Pereira, Patrícia
Neves, Márcia C.
Freire, Mara G.
Pedro, Augusto Q.
dc.subject.por.fl_str_mv Biopharmaceuticals
Purification
Supported ionic liquids
Chromatography
Aqueous twophase systems
IFNα-2b
topic Biopharmaceuticals
Purification
Supported ionic liquids
Chromatography
Aqueous twophase systems
IFNα-2b
description The development of protein-based biopharmaceuticals and their introduction on modern medicine brought enormous benefits to the treatment of life-threatening diseases such as cancer, diabetes and neurodegenerative disorders. However, their current high-cost still limits their widespread use. While significant advances at the upstream level have occurred, current purification strategies are unable to cope with high product concentrations resorting to cost-effective approaches. This work entails the development of sustainable downstream processing methodologies for recombinant interferon (IFN) α-2b derived from Escherichia coli using ionic liquids, either by exploring their application as adjuvants in polymer-polymer aqueous two-phase systems (ATPS) or as chromatographic ligands covalently attached in silica (supported ionic liquids - SILs). Overall, our results demonstrate the high potential exhibited by ionic liquids toward the preparative purification of the recombinant IFN α-2b biopharmaceutical.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-01T00:00:00Z
2021-06
2022-01-12T14:24:49Z
dc.type.driver.fl_str_mv conference object
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10773/32877
url http://hdl.handle.net/10773/32877
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv FEUP
publisher.none.fl_str_mv FEUP
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817543797153726464

Registros relacionados